ClinicalTrials.gg

Program

ganaplacide

Also written as “KAF156” and “Ganaplacide”.

In Novartis's pipeline, Non-artemisinin plasmodium falciparum inhibitor. Its studies are mostly in Malaria · Malaria, Falciparum, led by Novartis.

Furthest: phase 2, since Dec 17, 20127 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis70 open or runningphase 2since Dec 17, 2012Dec 17, 2012none ahead
  • Named in Novartis’s own pipeline as KLU156 (Ganaplacide + lumefantrine), phase 4, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2012First study: phase 2 study in MalariaFirst studyNCT01753323 · 43 enrolled · Thailand, Vietnam
  2. May 19, 2017Phase 2 study in Acute Uncomplicated Plasmodium Falciparum MalariaNCT03167242 · 524 enrolled · Burkina Faso, Gabon, India and more
  3. Aug 20, 2019Phase 1 study in MalariaNCT04072302 · 86 enrolled · United States
  4. Sep 5, 2020Phase 2 study in Malaria, FalciparumNCT04546633 · 295 enrolled · Burkina Faso, Côte d’Ivoire, Gabon and more
  5. Oct 6, 2021Phase 1 study in MalariaNCT05084651 · 19 enrolled · United Kingdom
  6. Feb 4, 2022Phase 1 study in MalariaNCT05236530 · 48 enrolled · United Kingdom
  7. Apr 8, 2022Phase 1 study in MalariaNCT05330273 · 14 enrolled · United Kingdom

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Non-artemisinin plasmodium falciparum inhibitor”the company's pipeline, read by Claude · source

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05330273Malaria · United Kingdom1CompletedNov 22, 202214
NCT05236530Malaria · United Kingdom1CompletedOct 17, 202248
NCT05084651Malaria · United Kingdom1CompletedMay 13, 202219
NCT04546633Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more2CompletedAug 13, 2024295
NCT04072302Malaria · United States1CompletedNov 29, 201786
NCT03167242Acute Uncomplicated Plasmodium Falciparum Malaria · Burkina Faso, Gabon, India and more2CompletedJun 14, 2021524
NCT01753323Malaria · Thailand, Vietnam2CompletedAug 201443

How it is read

Names in the registry

  • “KAF156”, 4 entries
  • “Ganaplacide”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.